Oxford BioDynamics (GB:OBD) has released an update.
Oxford BioDynamics partners with King’s College London to develop EpiSwitch biomarkers aiming to improve rheumatoid arthritis (RA) treatment strategies post-Abatacept therapy. The collaboration follows the APIPPRA trial, the largest RA prevention trial, which revealed the need for better patient stratification tools. This initiative promises to enhance the identification of individuals at high risk of RA and optimize their treatment outcomes.
For further insights into GB:OBD stock, check out TipRanks’ Stock Analysis page.
